- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting AKT for cancer therapy
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 11, Pages 977-988
Publisher
Informa UK Limited
Online
2019-10-09
DOI
10.1080/13543784.2019.1676726
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients.
- (2019) Cecile Vicier et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT isoform-specific expression and activation across cancer lineages
- (2018) Jue Wang et al. BMC CANCER
- Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
- (2018) K. Kalinsky et al. Clinical & Translational Oncology
- Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
- (2018) Belinda van Zyl et al. ENDOCRINE-RELATED CANCER
- A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
- (2018) Carol Aghajanian et al. INVESTIGATIONAL NEW DRUGS
- AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
- (2018) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Crosstalk in transition: the translocation of Akt
- (2018) Catheryn W. Gray et al. JOURNAL OF MATHEMATICAL BIOLOGY
- Capivasertib Active against AKT1-Mutated Cancers
- (2018) Cancer Discovery
- Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
- (2017) Eric Angevin et al. EUROPEAN JOURNAL OF CANCER
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- 446PDPHASE IB DOSE-ESCALATION STUDY OF THE AKT INHIBITOR IPATASERTIB (IPAT) WITH PACLITAXEL (P) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
- (2017) S.J. Isakoff et al. ANNALS OF ONCOLOGY
- AKT in cancer: new molecular insights and advances in drug development
- (2016) Prabhjot S. Mundi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models
- (2016) Oliver Politz et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53.
- (2016) Sungman Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
- (2016) Jean-Marc Lapierre et al. JOURNAL OF MEDICINAL CHEMISTRY
- Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
- (2016) C. Stottrup et al. MOLECULAR CANCER THERAPEUTICS
- AKT signaling in ERBB2-amplified breast cancer
- (2016) F. Javier Carmona et al. PHARMACOLOGY & THERAPEUTICS
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- P5.01 * A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies
- (2015) A. M. Tsimberidou et al. ANNALS OF ONCOLOGY
- 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma
- (2015) A. Tolcher et al. EUROPEAN JOURNAL OF CANCER
- Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies
- (2015) Weimin Fan et al. Future Medicinal Chemistry
- The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
- (2015) Seiji Mabuchi et al. GYNECOLOGIC ONCOLOGY
- A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer
- (2015) Analia Azaro et al. INVESTIGATIONAL NEW DRUGS
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
- (2015) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
- (2015) Kyung H. Yi et al. Oncotarget
- Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
- (2015) Marjorie J. Lindhurst et al. Scientific Reports
- SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
- (2015) Ana M. Gonzalez-Angulo et al. JNCI-Journal of the National Cancer Institute
- Abstract 4516: Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
- (2015) Bayard R. Huck et al. CANCER RESEARCH
- Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
- (2015) Yi Yu et al. PLoS One
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract C177: TAS-117, a highly selective non-ATP competitive inhibitor of AKT demonstrated antitumor activity in combination with chemotherapeutic agents and molecular targeted drugs.
- (2014) K. Ichikawa et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
- (2014) Melissa Dumble et al. PLoS One
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Regulation of YAP through an Akt-dependent process by 3, 3′-diindolylmethane in human colon cancer cells
- (2013) XIU JUAN LI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
- (2013) Matt Addie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
- (2013) Deepa Sampath et al. LEUKEMIA RESEARCH
- Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
- (2012) T. Sangai et al. CLINICAL CANCER RESEARCH
- Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
- (2012) D. A. Altomare et al. CURRENT MEDICINAL CHEMISTRY
- Suppression of survival signalling pathways by the phosphatase PHLPP
- (2012) Audrey K. O’Neill et al. FEBS Journal
- Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
- (2012) Siqing Fu et al. GYNECOLOGIC ONCOLOGY
- Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53
- (2012) Sungman Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Mouse Models of Cancer
- (2011) Dong-Joo Cheon et al. Annual Review of Pathology-Mechanisms of Disease
- Akt, FoxO and regulation of apoptosis
- (2011) Xinbo Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Breast cancer statistics, 2011
- (2011) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors
- (2011) Ahmad Awada et al. CANCER RESEARCH
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis
- (2011) Qing Xu et al. NUCLEIC ACIDS RESEARCH
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane
- (2010) N Berndt et al. CELL DEATH AND DIFFERENTIATION
- Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
- (2010) Christopher R. Garrett et al. INVESTIGATIONAL NEW DRUGS
- Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia
- (2010) Camilla Evangelisti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis
- (2009) Alexandra Dieterle et al. INTERNATIONAL JOURNAL OF CANCER
- Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen
- (2009) John McLaughlin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Akt as a therapeutic target in cancer
- (2008) Linda S Steelman et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
- The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development
- (2008) Deborah K. Morrison TRENDS IN CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now